Time filter

Source Type

Zhou S.-F.,Huazhong University of Science and Technology | Zhou S.-F.,Key Laboratory of Biological Targeted Therapy of the Ministry of Education | Yuan J.,Huazhong University of Science and Technology | Yuan J.,Key Laboratory of Biological Targeted Therapy of the Ministry of Education | And 29 more authors.
Journal of Molecular Medicine | Year: 2014

Inflammatory responses play an important role in the pathogenesis of adverse ventricular remodeling after myocardial infarction (MI). We previously demonstrated that interleukin (IL)-17A plays a pathogenic role in myocardial ischemia/reperfusion injury and viral myocarditis. However, the role of IL-17A in post-MI remodeling and the related mechanisms have not been fully elucidated. Acute MI was induced by permanent ligation of the left anterior descending coronary artery in C57BL/6 mice. Repletion of IL-17A significantly aggravated both early- and late-phase ventricular remodeling, as demonstrated by increased infarct size, deteriorated cardiac function, increased myocardial fibrosis, and cardiomyocyte apoptosis. By contrast, genetic IL-17A deficiency had the opposite effect. Additional studies in vitro indicated that IL-17A induces neonatal cardiomyocyte (from C57BL/6 mice) apoptosis through the activation of p38, p53 phosphorylation, and Bax redistribution. These data demonstrate that IL-17A induces cardiomyocyte apoptosis through the p38 mitogen-activated protein kinase (MAPK)-p53-Bax signaling pathway and promotes both early- and late-phase post-MI ventricular remodeling. IL-17A might be an important target in preventing heart failure after MI. © 2014, Springer-Verlag Berlin Heidelberg.


Zhu Z.-F.,Huazhong University of Science and Technology | Zhu Z.-F.,Key Laboratory of Biological Targeted Therapy of the Ministry of Education | Tang T.-T.,Huazhong University of Science and Technology | Tang T.-T.,Key Laboratory of Biological Targeted Therapy of the Ministry of Education | And 28 more authors.
Journal of Leukocyte Biology | Year: 2015

There has been increasing evidence that chronic immune activation plays critical roles in the pathogenesis of DCM. CD4+ LAP+ Tregs are a newly identified T cell subset with suppressive function on the immune response. This study was designed to investigate whether the circulating frequency and function of CD4+LAP+ Tregs would be impaired in patients with DCM. The results demonstrated that DCM patients had a significantly lower frequency of circulating CD4+LAP+ Tregs compared with control donors. CD4+LAP+ Tregs from DCM patients showed compromised function to suppress proliferation of CD4+ LAP2CD25int/low T cells and proliferation and IgG production of B cells. Moreover, B cell proliferation and IgG subset production could be directly suppressed by CD4+ LAP+ Tregs. TGF-b and contact-dependent mechanisms were involved in CD4+LAP+ Treg-mediated suppression. Correlation analysis suggested that CD4+LAP+ Treg frequency was positively correlated with LVEF and negatively correlated with serum IgG3 and NT-proBNP concentration in patients with DCM. Our results are the first to demonstrate that the frequencies of CD4+LAP+ Tregs in patients with DCM are reduced and that their suppressive function is compromised. Defective CD4+ LAP+ Tregs may be an underlying mechanism of immune activation in DCM patients. © Society for Leukocyte Biology.


PubMed | LKey Laboratory of Biological Targeted Therapy of the Ministry of Education, Cardio nter and Key Laboratory of Biological Targeted Therapy of the Ministry of Education
Type: | Journal: The Journal of biological chemistry | Year: 2016

CD4+ T cells are abnormally activated in patients with dilated cardiomyopathy (DCM) and might be associated with the immunopathogenesis of the disease. However, the underlying mechanisms of CD4+ T cell activation remain largely undefined. Our aim was to investigate whether the dysregulation of microRNAs (miRNAs) was associated with CD4+ T cell activation in DCM. CD4+ T cells from DCM patients showed increased expression levels of CD25 and CD69 and enhanced proliferation in response to anti-CD3/28, indicating an activated state. MiRNAs profiling analysis of magnetically sorted CD4+ T cells revealed a distinct pattern of miRNAs expression in CD4+ T cells from DCM patients compared with controls. The level of miRNA-451a (miR-451a) was significantly decreased in the CD4+ T cells of DCM patients compared with that of the controls. The transfection of T cells with a miR-451a mimic inhibited their activation and proliferation, whereas a miR-451a inhibitor produced the opposite effects. Myc was directly inhibited by miR-451a via interaction with its 3-UTR, thus identifying it as a miR-451a target in T cells. The knockdown of Myc suppressed the activation and proliferation of T cells, and the expression of Myc was significantly up-regulated at the mRNA level in CD4+ T cells from patients with DCM. A strong inverse correlation was observed between the Myc mRNA expression and miR-451a transcription level. Our data suggest that the down-regulation of miR-451a contributes to the activation and proliferation of CD4+ T cells by targeting the transcription factor Myc in DCM patients, and may contribute to the immunopathogenesis of DCM.

Loading Key Laboratory of Biological Targeted Therapy of the Ministry of Education collaborators
Loading Key Laboratory of Biological Targeted Therapy of the Ministry of Education collaborators